These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8957053)

  • 41. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 42. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract]   [Full Text] [Related]  

  • 43. Reduced delayed graft function (DGF) after cadaveric kidney transplantation (CKT) with selective OKT3 induction and aggressive intraoperative management.
    Taylor RJ; Stratta RJ; Zorn BH; Langnas AN; Shaw BW
    Transplant Proc; 1991 Oct; 23(5):2317-8. PubMed ID: 1926370
    [No Abstract]   [Full Text] [Related]  

  • 44. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA; Khawand N; Aquino A; Ali A; Korb S
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. OKT3 versus methylprednisolone for primary treatment of rejection: a retrospective evaluation.
    Meijer RT; Keur I; Surachno S; ten Berge IJ; Schellekens PT
    Transplant Proc; 2001 May; 33(3):2196-7. PubMed ID: 11377501
    [No Abstract]   [Full Text] [Related]  

  • 47. Predicting factors for long-term results of OKT3 therapy in steroid-resistant acute rejection following cadaveric renal transplantation.
    Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
    Transplant Proc; 1998 Jun; 30(4):1170-2. PubMed ID: 9636473
    [No Abstract]   [Full Text] [Related]  

  • 48. A drug of the past, a lesson for the future.
    Vincenti F
    Pediatr Transplant; 2005 Jun; 9(3):267-8. PubMed ID: 15910379
    [No Abstract]   [Full Text] [Related]  

  • 49. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

  • 50. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.
    Lazarovits AI; Rochon J; Banks L; Hollomby DJ; Muirhead N; Jevnikar AM; White MJ; Amlot PL; Beauregard-Zollinger L; Stiller CR
    Transplant Proc; 1993 Feb; 25(1 Pt 1):820-2. PubMed ID: 7679844
    [No Abstract]   [Full Text] [Related]  

  • 51. Influence of donor-recipient HLA-DR mismatches and OKT3 prophylaxis on cadaver kidney graft survival.
    Vereerstraeten P; Dupont E; Andrien M; De Pauw L; Abramowicz D; Goldman M; Kinnaert P
    Transplantation; 1995 Aug; 60(3):253-8. PubMed ID: 7645038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of short-term OKT3 therapy in the treatment of steroid-resistant renal allograft rejection.
    Carvalho MF; Adoni T; Saggioro FP; Soares V
    Transplant Proc; 1998 Sep; 30(6):2876-7. PubMed ID: 9745607
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 54. HaNDL syndrome after "benign" OKT3-induced meningitis.
    Thomas MC; Walker R; Wright A
    Transplantation; 1999 May; 67(10):1384-5. PubMed ID: 10360598
    [No Abstract]   [Full Text] [Related]  

  • 55. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation.
    Deierhoi MH; Sollinger HW; Diethelm AG; Belzer FO; Kauffman RS
    Transplant Proc; 1993 Feb; 25(1 Pt 1):693-4. PubMed ID: 8438440
    [No Abstract]   [Full Text] [Related]  

  • 56. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
    First MR
    Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
    [No Abstract]   [Full Text] [Related]  

  • 57. Delayed graft function of cadaveric renal transplants is prevented by diltiazem.
    Carmellini M; Salvadori M; Di Stefano R; Bertoni E; Nicita G; Rosati A; Taddei G; Rindi P; Rizzo G; Mosca F
    Transplant Proc; 1996 Feb; 28(1):80-2. PubMed ID: 8644348
    [No Abstract]   [Full Text] [Related]  

  • 58. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
    Baldi A; Malaise J; Mourad M; Squifflet JP
    Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467
    [No Abstract]   [Full Text] [Related]  

  • 59. The fate of renal allografts treated with OKT3 for steroid-resistant rejection.
    Veronese FV; Gonçalves LF; Vilarinho LL; Macedo VS; Manfro RC
    Transplant Proc; 1999 Nov; 31(7):3016-8. PubMed ID: 10578371
    [No Abstract]   [Full Text] [Related]  

  • 60. OKT3 in renal allografts: survival and complications.
    D'Souza RJ; Kwan JT; Chang R; Bending MR
    Clin Nephrol; 1999 Apr; 51(4):257-8. PubMed ID: 10230561
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.